Wearable Continuous BP Monitoring 2026 — PatSnap Eureka
Wearable Continuous Blood Pressure Monitoring: The 2026 Innovation Landscape
From PTT/PWV to AI-calibrated multi-modal fusion, the cuffless BP monitoring field spans 18 years of patent filings across 1.4 billion hypertension patients globally. Explore the full technology landscape with PatSnap Eureka.
Four Dominant Sensing Clusters in Wearable cBP
The wearable continuous blood pressure monitoring field is defined by four principal technology clusters, each with distinct signal sources, calibration requirements, and regulatory implications — as evidenced by patent records spanning 2008 to 2026.
PTT / PWV-Based Continuous Cuffless BP
Measures the propagation time of the arterial pulse between two body sites as a proxy for arterial stiffness and blood pressure. Signal pairs include ECG-to-PPG (most common), SCG-to-PPG, or dual PPG at different anatomical locations. Key filings include Sotera Wireless (CN, 2012), Fourth Frontier Technologies (IN, 2024), and Euler Health (CN, 2025). Oxford BioHorizons (2021) confirms ongoing calibration challenges driven by individual vascular variability.
Requires periodic cuff calibrationPPG Morphology and Empirical ML Models
Extracts waveform shape features — amplitude ratios, systolic/diastolic areas, second derivatives, dicrotic notch parameters — from a single PPG sensor and maps them to blood pressure through regression or neural network models. ECHO Labs (EP, 2021), Spry Health (EP, 2023), and Samsung Electronics (JP, 2023) are prominent in this cluster. Samsung extracts first and second cardiovascular features and estimates SBP and DBP based on independent changing tendencies relative to reference cardiovascular features.
Single-sensor wrist deploymentMulti-Modal AI-Calibrated Continuous BP
The most active recent cluster fuses ECG, PPG, seismocardiogram (SCG), phonocardiogram (PCG), and accelerometer signals through machine learning models, with periodic self-calibration strategies that eliminate or reduce the need for a reference cuff. Key filings from Covidien LP (EP, 2023), Vital Connect (EP, 2025), WHOOP (WO, 2025), and Aio Medical Devices Shenzhen (CN, 2025). Regulatory filings converge on multi-signal validation to satisfy IEEE/ISO and FDA error bounds for cuffless BP devices.
AI drift correction · no scheduled cuffDirect Pressure Sensing and Applanation Arrays
A physically distinct approach using piezoelectric or capacitive pressure sensor arrays placed directly over the radial artery to record the arterial waveform without inferring it from optical signals. LiveMetric (Medical) S.A. (US, 2025) deploys wearable pressure sensor arrays to quantify arterial waveform changes before and after drug administration — enabling quantified medication response evaluation. WHOOP's haptic-optical hybrid (WO, 2024) applies varying haptic-driven force while measuring optical response to derive a subject-specific BP model.
Beat-to-beat arterial waveformThree Generational Shifts in Wearable cBP Innovation
Foundational period (2008–2014): Early filings focused on system architecture and body-worn sensor networks. The headset-based physiological parameter system (Pedro Girão, PT, 2008) and multi-distributed physiological monitoring system (CN, 2009) established wireless multi-sensor concepts. The Sotera Wireless body-worn cNIBP system (CN, 2012) and HealthStats arterial contact sensor (PT, 2011) represent early cuffless continuous BP attempts. LiDCO Group filings in Japan (2011, 2013) define hemodynamic monitoring via continuous arterial pressure waveform analysis.
Development and proliferation period (2017–2022): Significant filing activity from Samsung Electronics, Vital Connect, ECHO Labs / Spry Health, Covidien, and Philips. Wearable form factors consolidated around the wrist. Philips' trained predictive model (JP, 2021) derives daytime-to-nighttime BP drop as a cardiovascular risk indicator — a signal of growing clinical ambition in the field.
Recent acceleration period (2023–2026): Convergence on AI-driven calibration, multi-posture adaptation (Samsung, EP, 2025), sleep-specific BP triggering (Huawei, CN, 2025), multi-wearable pulse timing (Euler Health, CN/JP, 2025), and vascular stiffness assessment fused with AI risk scoring (Shenzhen Xinrui Technology, CN, 2026). Becton Dickinson hemodynamic monitors for cardiac triage appear in JP 2025, indicating clinical-grade wearable integration. According to WHO, hypertension remains the leading preventable cause of cardiovascular death globally, underpinning the urgency of this innovation wave.
Geographic Filing Distribution and Innovation Velocity
Analysis of retrieved patent records spanning 2008 to early 2026, visualising jurisdictional filing counts and the generational acceleration of wearable cBP innovation activity.
Patent Filing Activity by Jurisdiction
Korea leads with 20+ filings; Japan hosts 15 filings primarily from overseas assignees; China is second most active with 10+ filings concentrated in 2024–2026.
Innovation Velocity: Filings by Generational Period
Three distinct generational waves are visible: foundational (2008–2014), proliferation (2017–2022), and recent acceleration (2023–2026) with the sharpest increase in AI-calibrated approaches.
Where Wearable cBP Technology Is Being Deployed
Patent filings reveal seven distinct application domains, from chronic hypertension management to surgical perioperative settings and emerging cross-domain applications.
| Application Domain | Key Assignees / Filings | Distinguishing Feature | Jurisdiction |
|---|---|---|---|
| Chronic Disease / Hypertension | Huawei Technologies, Shenzhen Liandai Technology, Euler Health | Sleep-triggered BP measurement; 24-hour ambulatory profiles | CN, 2025 |
| Cardiovascular Triage / CDS | Becton Dickinson, Edwards Lifesciences, LiDCO Group | Aortic stenosis detection; stroke volume from arterial waveforms | JP, 2025 / JP, 2020 |
| Medication Response Monitoring | LiveMetric (Medical) S.A. | Beat-to-beat waveform comparison pre- and post-drug administration | US/WO, 2023/2025 |
| Sleep and Nighttime Monitoring | Huawei Technologies, Shenzhen Liandai Technology, Philips | OSA/REM/NREM-triggered measurement; daytime-to-nighttime BP drop | CN, 2025 / JP, 2021 |
| Surgical / Perioperative | Shenzhen Pingshan District Central Hospital | Real-time patient anxiety composite index from BP + HR variability | CN, 2025 |
| Special Population / Field | "Ghaith" bracelet (SA), Korean Research Institute of Standards | BLE crowd monitoring; cardiovascular risk scoring for stroke prevention | SA, 2025 / KR, 2021 |
| Glaucoma / Ocular Pressure | Yonsei University | Finger ring pulse wave infers systemic BP as input to glaucoma risk | KR, 2025 |
Map Competitive White Space in Wearable cBP Applications
Use PatSnap IP analytics to identify underserved application domains and emerging assignee clusters before they become crowded.
Six Emerging Directions Shaping the Next Wave
Based on filings dated 2024–2026 in this dataset, these directional signals indicate where wearable cBP technology is heading over the next product generation.
Sleep-Contextualized BP Monitoring
Huawei (CN, 2025) and Shenzhen Liandai Technology (CN, 2025) explicitly target sleep-event-triggered BP measurement, gating measurement to detected OSA, REM, or NREM events rather than measuring continuously — reflecting growing recognition that nocturnal BP is more predictive of cardiovascular mortality than daytime BP.
Multi-Device Pulse Timing Networks
Euler Health (CN, 2025) and Oura Health (JP, 2025) independently explore using two or more wearable devices — worn at different body sites or depths — to triangulate PTT without ECG electrodes, potentially enabling ring-plus-smartwatch or ear-plus-wrist configurations.
Vascular Stiffness and Arterial Age Scoring
Shenzhen Xinrui Technology (CN, 2026) and Aio Medical Devices (CN, 2025) move beyond SBP/DBP point values toward continuous vascular stiffness indices — arterial stiffness modulus, pulse wave velocity trends, aortic hardening risk scores — representing a shift from blood pressure measurement to vascular health profiling.
Haptic-Optical Hybrid Calibration
WHOOP's two filings (WO 2024, WO 2025) introduce haptic actuators to mechanically stimulate tissue and measure the optical response, enabling device-internal calibration without any cuff or external reference. This is a significant architectural shift that could unlock fully autonomous calibration in consumer wearables.
What This Landscape Means for R&D and IP Strategy
Calibration is the central unsolved problem. The majority of filings involve some form of calibration strategy — periodic cuff, ML drift correction, haptic self-calibration, or multi-device PTT. R&D teams should prioritize calibration robustness across postures, skin tones, activity states, and vascular conditions as the primary differentiator for clinical-grade regulatory clearance.
The regulatory pathway favors multi-signal fusion. Filings from Vital Connect (ECG+PPG+PCG), Fourth Frontier (ECG+SCG+PPG), and Covidien (PPG+AI calibration) all converge on multi-signal validation — likely because multi-modal architectures can better satisfy the error bounds required by IEEE/ISO and FDA for cuffless BP devices.
Consumer platforms are converging on clinical-grade measurement. Samsung's posture-adaptive calibration (EP, 2025), WHOOP's haptic-optical calibration (WO, 2024/2025), and Oura's PPG morphology cardiovascular health metric (JP, 2025) signal that the consumer-clinical boundary is collapsing. Product developers must design for both consumer usability and clinical validation standards simultaneously. The PatSnap customer network includes leading medtech and consumer device teams navigating exactly this challenge.
Vascular health profiling is the next competitive frontier. Multiple recent filings frame the value proposition not as "measuring BP" but as computing vascular age, stiffness indices, and aortic hardening risk. This shift broadens the addressable market from hypertension management to proactive cardiovascular risk prevention and creates differentiated data assets for health insurance and pharmaceutical partners. According to NIH, arterial stiffness is an independent predictor of cardiovascular events beyond traditional BP values.
For teams building or defending IP in this space, PatSnap's life sciences intelligence platform provides real-time monitoring of CN filings from Huawei, Euler Health, and Shenzhen-based startups — the fastest-growing cluster in this landscape.
Wearable Continuous Blood Pressure Monitoring — key questions answered
Wearable continuous blood pressure monitoring encompasses a spectrum of non-invasive techniques that measure surrogate physiological signals and translate them into systolic (SBP) and diastolic (DBP) blood pressure values without requiring an inflatable cuff, worn on the wrist, finger, chest, or ear.
The dominant approaches include Pulse Transit Time / Pulse Wave Velocity (PTT/PWV), PPG Morphology and Feature Extraction, Pressure Sensor Array / Applanation Tonometry, AI/ML-Calibrated Multi-Modal Fusion, and Non-contact and Novel Imaging Modalities such as IR imaging and millimeter-wave radar.
Samsung Electronics, iRhythm Technologies, WHOOP Inc., LiveMetric (Medical) S.A., and Vital Connect emerge as multi-filing entities. Samsung is distinct in combining hardware wearable design with signal processing patents. WHOOP uniquely bridges consumer wearable form factors with medically-oriented ML calibration approaches across multiple filings.
Calibration remains the central unsolved problem. The majority of filings involve some form of calibration strategy — periodic cuff, ML drift correction, haptic self-calibration, or multi-device PTT. R&D teams should prioritize calibration robustness across postures, skin tones, activity states, and vascular conditions as the primary differentiator for clinical-grade regulatory clearance.
China is the fastest-growing filing jurisdiction for cBP innovation in 2024–2026. CN filings are concentrated in the 2024–2026 window, signaling rapid recent scale-up. IP strategists entering or defending this space must actively monitor CN filings, particularly from Huawei, Euler Health, and deep-tech startups in Shenzhen.
Vascular health profiling — not just BP numbers — is the next competitive frontier. Multiple recent filings frame the value proposition not as measuring BP but as computing vascular age, stiffness indices, and aortic hardening risk. This shift broadens the addressable market from hypertension management to proactive cardiovascular risk prevention.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About cBP PatentsAccelerate Your Wearable cBP R&D with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from calibration strategy to vascular stiffness profiling.
References
- Body-worn system for measuring continuous non-invasive blood pressure (cNIBP) — Sotera Wireless, Inc., 2012, CN
- A system and method for continuous monitoring of blood pressure — Fourth Frontier Technologies Pvt. Ltd., 2024, IN
- System for determining blood pressure based on relative pulse timing — Euler Health (Aura Health), 2025, CN
- Systems and methods for non-invasive blood pressure measurement — ECHO Labs, Inc., 2021, EP
- Systems and methods for non-invasive blood pressure measurement — Spry Health, Inc., 2023, EP
- Blood pressure estimation device and method, and wearable device — Samsung Electronics Co., Ltd., 2023, JP
- Calibration for continuous non-invasive blood pressure monitoring using artificial intelligence — Covidien LP, 2023, EP
- Non-invasive blood pressure measurement and monitoring — Vital Connect, Inc., 2025, EP
- Blood pressure evaluation with machine learning — WHOOP, Inc., 2025, WO
- AI-based continuous blood pressure anomaly early warning method and system — Aio Medical Devices (Shenzhen) Co., Ltd., 2025, CN
- Non-invasive continuous blood pressure monitoring — SHAH, NITAGAURI, 2020, SG
- Devices and methods for predicting effect of a cardiovascular medication administration program — LiveMetric (Medical) S.A., 2025, US
- Blood pressure measurement with haptic calibration — WHOOP, Inc., 2024, WO
- Wearable electronic apparatus for measuring blood pressure and operating method therefor — Samsung Electronics Co., Ltd., 2025, EP
- Wearable continuous blood pressure monitoring device and system — Shenzhen Liandai Technology Co., Ltd., 2025, CN
- Blood pressure detection method, wearable device, and storage medium — Huawei Technologies Co., Ltd., 2025, CN
- System and method for non-invasive determination of blood pressure reduction based on a trained predictive model — Koninklijke Philips N.V., 2021, JP
- Determining Cardiovascular Health Metrics from Wearable-Based Physiological Data — Oura Health Oy, 2025, JP
- System and method for artificial intelligence-based blood pressure calculation based on extraocular images — O/D Vision Inc., 2025, JP
- Multi-parameter collaborative cardiovascular health monitoring system and method — Nanchang University, 2025, CN
- Vascular function detection method based on multi-physiological signal fusion and related products — Shenzhen Xinrui Technology Co., Ltd., 2026, CN
- Devices and methods for evaluating the response to and/or the effectiveness of a cardiovascular medication administration program — LiveMetric (Medical) S.A., 2023, WO
- Method and device for monitoring blood pressure — HealthStats International Pte Ltd, 2011, PT
- Hemodynamic monitoring for triage of patients with aortic stenosis — Becton Dickinson and Company, 2025, JP
- Cuffless blood pressure estimation based on haemodynamic principles: progress towards mobile healthcare — Oxford BioHorizons Ltd., 2021, Literature
- World Health Organization (WHO) — Hypertension and Cardiovascular Disease Global Data
- IEEE — Standards for Wearable Blood Pressure Measurement Devices
- U.S. Food and Drug Administration (FDA) — Cuffless Blood Pressure Measuring Devices Guidance
- National Institutes of Health (NIH) — Arterial Stiffness as Cardiovascular Risk Predictor
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.